



Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19

March 11, 2019 4:04 PM EDT

SOUTH SAN FRANCISCO, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF (**Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure**), a Phase 2 trial evaluating *omecamtiv mecarbil* in patients with chronic heart failure, will be presented in a Moderated Poster Session at the American College of Cardiology's 68th Annual Scientific Session (ACC.19) in New Orleans on March, 18, 2019.

Title: Effect of *Omecamtiv Mecarbil* in Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction: Results From COSMIC-HF

Speaker: John Teerlink, M.D., Professor of Clinical Medicine, University of California San Francisco and Director of Heart Failure, San Francisco Veterans Affairs Medical Center

Session: Heart Failure and Cardiomyopathies: Latest Discoveries in Basic, Translational and Clinical Science

Date: March 18, 2019

Presentation Time: 1:00 – 1:10 PM CT

Location: New Orleans Ernest N. Morial Convention Center, Poster Hall, Hall F

About *Omecamtiv Mecarbil* and the Phase 3 Clinical Trials Program

Omecamtiv mecarbil is a novel, selective cardiac myosin activator that binds to the catalytic domain of myosin. Preclinical research has shown that cardiac myosin activators increase cardiac contractility without affecting intracellular myocyte calcium concentrations or myocardial oxygen consumption.^{i,ii,iii} Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction.

Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF) under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier. *Omecamtiv mecarbil* is the subject of a comprehensive Phase 3 clinical trials program comprised of GALACTIC-HF (**Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure**), a large, Phase 3 global cardiovascular outcomes study being conducted by Amgen in collaboration with Cytokinetics, with the support of Servier and METEORIC-HF (**Multicenter Exercise Tolerance Evaluation of *Omecamtiv Mecarbil*/Related to Increased Contractility in Heart Failure**), a Phase 3 clinical trial designed to evaluate the effect of treatment with *omecamtiv mecarbil* compared to placebo on exercise capacity, being conducted by Cytokinetics in collaboration with Amgen, with support from Servier.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is collaborating with Amgen Inc. (Amgen) to develop *omecamtiv mecarbil*, a novel cardiac muscle activator. *Omecamtiv mecarbil* is the subject of an international clinical trials program in patients with heart failure including GALACTIC-HF and METEORIC-HF. Amgen holds an exclusive worldwide license to develop and commercialize *omecamtiv mecarbil* with a sublicense held by Servier for commercialization in Europe and certain other countries. Cytokinetics is collaborating with Astellas Pharma Inc. (Astellas) to develop *rel-desemtiv*, a fast skeletal muscle troponin activator (FSTA). *Rel-desemtiv* has been granted orphan drug designation by the FDA for the potential treatment of spinal muscular atrophy. *Rel-desemtiv* was the subject of a Phase 2 clinical study in patients with spinal muscular atrophy which showed increases in measures of endurance and stamina consistent with the mechanism of action. *Rel-desemtiv* is currently the subject of a Phase 2 clinical trial in patients with amyotrophic lateral sclerosis. Astellas holds an exclusive worldwide license to develop and commercialize *rel-desemtiv*. Licenses held by Amgen and Astellas are subject to specified co-development and co-commercialization rights of Cytokinetics. Cytokinetics is also developing CK-274, a novel cardiac myosin inhibitor that company scientists discovered independent of its collaborations, for the potential treatment of hypertrophic cardiomyopathies. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities; the timing of enrollment of patients in Cytokinetics' and its partners' clinical trials; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas' decisions with respect to the design, initiation, conduct, timing and continuation of development activities for *rel-desemtiv*; Amgen's decisions with respect to the design, initiation, conduct, timing and continuation of development activities for *omecamtiv mecarbil*; standards of care may change, rendering Cytokinetics' drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics' collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact:

Cytokinetics

Diane Weiser
Vice President, Corporate Communications, Investor Relations
(415) 290-7757

ⁱ Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J. et al. Mechanistic and structural basis for activation of cardiac myosin force production by *omecamtiv mecarbil*. *Nat Commun*. 2017;8:190.

ⁱⁱ Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. *Circ Heart Fail*. 2010; 3: 522-27.

ⁱⁱⁱ Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. *Science*. 2011 Mar 18;331(6023):1439-43.



Source: Cytokinetics, Incorporated